Publication | Closed Access

Targeted co-delivery of epirubicin and NAS-24 aptamer to cancer cells using selenium nanoparticles for enhancing tumor response in vitro and in vivo

NanomedicineTumor BiologyDrug TargetingNanotherapeuticsPolymer-drug ConjugateNas-24 AptamerMedicineDrug Delivery SystemsNano-drug DeliveryTumor TargetingCancer CellsSelenium NanoparticlesPharmacologyRadiation OncologyCancer Research